Moderna (NASDAQ: MRNA) reported Q1 revenue for the quarter came in at $16.03 million versus the consensus estimate of $32.1 million.

“We continue to execute against our corporate objectives as we progress clinical studies across our development portfolio, introduce a new mRNA rare disease development candidate and focus on identifying additional modalities and disease targets,” said Stéphane Bancel, Moderna’s chief executive officer. “We are excited to pursue a treatment to potentially address the underlying cause of glycogen storage disease type 1a, and we believe this candidate also reflects the continued productivity of our mRNA platform. At yesterday’s annual Science Day event, we presented new insights into our mRNA and delivery science, including the potential delivery of mRNA to white blood cells. While our team has additional research to perform in this area, we look forward to being able to bring new candidates into development as we continue working to help patients with a wide range of serious diseases.”

For earnings history and earnings-related data on Moderna (MRNA) click here.